RoosterBio launches next generation EV collection media as part of a complete hMSC-EV production system

Share Article

RoosterCollect EV Pro™ significantly increases EV yields and accelerates scalable hMSC-EV therapeutic product development

RoosterBio Inc

RoosterCollect EV Pro is a step change in our customer-focused hMSC EV solutions. Increasing bioproduction efficiency and economy of scale are critical to rapidly advance this field. - RoosterBio Founder and Chief Product Officer Jon A. Rowley.

RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems, today announced the launch of its product RoosterCollect EV Pro™, bringing next level productivity to hMSC-derived extracellular vesicles (EV) production. RoosterCollect EV Pro is integral to the hMSC-EV production system offered by RoosterBio, which is engineered to enable hMSC-EV product developers to generate larger quantities EVs, faster than ever before.

RoosterCollect EV Pro is a media kit designed for post-cell expansion EV production and collection, which can prolong the EV collection phase leading to desirable increased EV yields, all while maintaining EV consistency and purity. This product, along with RoosterBio’s high-volume, xeno-free hMSCs and bioprocess media systems continues to industrialize the hMSC-EV supply chain with scalable, translation-friendly formats. RoosterCollect EV Pro is supported by processes that were developed to increase productivity in 3D (fed-batch) bioreactor applications. It also translates readily to 2D (batch) applications to meet product development needs.

Today, dozens of companies are developing EV/exosome-based therapeutic products to address diverse indications across regenerative medicine. The EV total market rapidly grows with at least 10,000 scientific articles published according to PubMed.gov, and over 100 related clinical trials are planned or in progress. hMSCs are known to be prolific producers of EVs, and it’s believed that a significant part of this cell type’s mechanism of action is due to EV secretion. EVs are also being innovated on as multivalent, targetable and controlled drug delivery systems for small molecules and/or macromolecular cargoes like siRNA, miRNA, or proteins.

“RoosterCollect EV Pro is a step change in our customer-focused hMSC EV solutions. Increasing bioproduction efficiency and economy of scale are critical to rapidly advance this field. This major industry challenge is what RoosterCollect EV Pro was engineered to meet,” said RoosterBio Founder and Chief Product Officer Jon A. Rowley. “Bioprocess innovations are positively shaping the nascent clinical and commercial EV product manufacturing landscape.”

About RoosterBio, Inc.

RoosterBio, Inc. is a privately held cell manufacturing platform technology company focused on accelerating the development of a sustainable Regenerative Medicine industry, one customer at a time. RoosterBio's products are high-volume, cost-effective, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how living cells are purchased, expanded, and used in development, leading to marked time and cost savings for customers. RoosterBio's innovative products and collaborative relationships are ushering in a new era of productivity and standardization into the field. Visit http://www.roosterbio.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Carrie Zhang
@RoosterBio
Follow >
Visit website